Publication of Inside Information according to Article 17 MAR
Epigenomics AG issues new shares by way of private placement
Not for distribution in the United States of America
Berlin, Germany, November 16, 2016 – Epigenomics AG, Berlin, Germany (Prime Standard Segment, Frankfurt: ECX, ISIN: DE0000A11QW50), announces that the Company is raising EUR 2.1 million of gross proceeds in a share capital increase by way of private placement.
The Executive Board of Epigenomics AG, with approval of the Supervisory Board, has today resolved on the increase of the Company’s share capital in the amount of EUR 474,800.00 by issuing 474,800 new registered shares of the Company from the Authorized Capital 2016/I against contribution in cash. The issue price has been set at EUR 4.52 per share. The new shares will carry dividend rights from January 1, 2016.
The capital increase was fully subscribed by Cathay Fortune International Company Limited, an institutional investor from China.
Following the registration of the capital increase with the commercial register (“Handelsregister”) – and subject to the registration of the capital increase resolved on November 7, 2016 – the subscribed capital of Epigenomics AG will increase to EUR 22,054,005.00. The admission of the new shares to the regulated market (prime standard) of the Frankfurt Stock Exchange is expected during December 2016. The technical implementation of the capital increase is conducted by Bankhaus Neelmeyer, Bremen, Germany.
Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to expand the U.S commercialization capacities for its lead product Epi proColon.
-End of publication –
Greg Hamilton, Chief Executive Officer of Epigenomics AG, commented: ““We are delighted to add Cathay Fortune International Company as a significant investor. Cathay Fortune’s diverse and knowledgeable resources are representative of the growing interest of major investors from China as expressed in the recent capital measures. With a combined ownership of more than 15%, BioChain, SummitView Capital and Cathay Fortune have become the top three shareholders of Epigenomics, sharing our belief in the great commercial potential of our liquid biopsy platform worldwide.”
This publication is not an offer of any securities for sale or a solicitation of an offer to purchase any securities.
This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the “Shares”) have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the Shares in the United States and the Shares will not be registered under the Securities Act.
Contact Epigenomics AG
Vice President Corporate Communications & Investor Relations
Phone +49 (0) 30 24345 386